News
VALN
5.23
+1.16%
0.06
Valneva says Goldman Sachs cuts stake to 4.14% (7,858,999 shares)
PUBT · 1d ago
Weekly Report: what happened at VALN last week (0622-0626)?
Weekly Report · 1d ago
Valneva says Goldman Sachs lifts beneficial stake to 5.21%
PUBT · 4d ago
Valneva Shareholders Back All AGM Resolutions as Board Elects New Chair
TipRanks · 5d ago
Valneva names Gerd Zettlmeissl board chair, replacing Anne-Marie Graffin
PUBT · 5d ago
Weekly Report: what happened at VALN last week (0615-0619)?
Weekly Report · 06/22 10:38
Weekly Report: what happened at VALN last week (0608-0612)?
Weekly Report · 06/15 10:38
Emergent BioSolutions: Down 40%+ From Recent Highs And Likely More To Come
Seeking Alpha · 06/08 21:27
Weekly Report: what happened at VALN last week (0601-0605)?
Weekly Report · 06/08 10:33
Valneva Publishes Documentation for June 25, 2026 Annual General Meeting
TipRanks · 06/05 11:08
Valneva files to sell 31.79M ordinary shares for holders
TipRanks · 06/04 21:10
Valneva announces annual general meeting documentation availability
PUBT · 06/04 05:00
Citadel Advisors discloses net short position in Valneva shares
PUBT · 06/02 14:49
Valneva Ramps Up June 2026 Investor and Medical Conference Presence
TipRanks · 06/01 15:12
Valneva management to present at Jefferies Global Healthcare Conference
PUBT · 06/01 14:02
Weekly Report: what happened at VALN last week (0525-0529)?
Weekly Report · 06/01 10:39
Valneva management presents at Jefferies Global Healthcare Conference
PUBT · 05/28 15:45
Citadel Advisors discloses net short position in Valneva shares
PUBT · 05/28 15:42
CDC drops below 10% voting rights threshold in Valneva, holds 9.33% voting stake
PUBT · 05/28 15:14
First Berlin reiterates Buy on Valneva, cuts price target to EUR 4.5
PUBT · 05/28 15:08
More
Webull provides a variety of real-time VALN stock news. You can receive the latest news about Valneva Se through multiple platforms. This information may help you make smarter investment decisions.
About VALN
Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.